Generate Biomedicines (GENB) Q3 FY2026 earnings: revenue $4 million, down 56.2% on the year

Generate Biomedicines, Inc. (GENB) reported revenue of $4 million for Q3 FY2026, the quarter ended 30 September 2026, down 56.2% on the same quarter a year earlier. Net income was -$88 million, and diluted earnings per share $-0.68. The figures are the company's own, from the 10-Q it filed with the SEC on 12 November 2026.

Revenue

$4 million

-56.2% on the year · -33.2% on the quarter

Q1 FY2025Q3 FY2026

Operating margin

-2168.4%

-652.0% a year earlier

Q1 FY2025Q3 FY2026

Net income

-$88 million

Q1 FY2025Q3 FY2026

Diluted EPS

-$0.68

Q1 FY2025Q3 FY2026

this quarterthe same quarter a year earlierHover a bar for its figure.

What management said

Guidance figures: 1 kept.

Net loss widened to $87.7 million: Net loss was $87.7 million, against $60.0 million a year earlier. Noncash stock-based compensation was $8.1 million, against $4.8 million in the prior-year quarter.
Two Phase 3 SOLAIRIA studies ongoing: Management reported the two global Phase 3 SOLAIRIA studies are ongoing in adults and adolescents with severe uncontrolled asthma. GB-0895 is the company's most advanced internal candidate.
GB-5267 first patient dosed in October: The first patient was dosed in the Phase 1 study of GB-5267, an autologous IL-18-armored CAR T therapy in platinum-resistant ovarian cancer, announced with Roswell Park on Oct. 1.

Read the earnings call summary

Income statement (profit and loss)

$ million	Q3 FY2026	Q2 FY2026	Q3 FY2025	On the quarter	On the year
Revenue	4.2	6.3	9.6	-33.2%	-56.2%
Research and development	82.3	64.3	62.2	+27.9%	+32.3%
Operating income	-91.5	-71.6	-62.8
Operating margin	-2168.4%	-1134.2%	-652.0%
Interest expense	0.2	0.2	0.3	+23.9%	-24.1%
Pre-tax income	-87.6	-67.2	-60.0
Income tax	0.0	0.1	0.0	-7.5%	+44.1%
Net income	-87.7	-67.3	-53.6
Net margin	-2077.2%	-1065.2%	-556.5%
Diluted EPS	-$0.68	-$0.52	-$1.97

$ million except per share.

Free cash flow is operating cash flow less capital expenditure; the effective tax rate is income tax over pre-tax income; margins are the line over revenue. Gross profit is revenue less cost of revenue, and operating income is revenue less the company's own total costs, where the statement does not print those lines. Those four are arithmetic on the filed numbers; everything else is as filed. Money is in $ million as the company files it, or in $ billion by the switch above the tables; per share figures and share counts are as they are.

Cash flow

$ million	Q3 FY2026	Q2 FY2026	Q3 FY2025	On the quarter	On the year
Operating cash flow	-54.9	-57.9	-48.4
Capital expenditure	2.2	0.9	0.2	+131.0%	+817.0%
Free cash flow	-57.0	-58.9	-48.7
Free cash flow margin	-1351.0%	-932.5%	-505.1%
Cash from investing	56.4	33.3	9.2	+69.2%	+513.7%
Cash from financing	3.5	-0.6	3.8		-7.9%
Depreciation and amortisation	3.7	3.2	3.3	+15.6%	+12.1%
Share-based compensation	8.1	8.2	4.8	-2.2%	+67.3%
Diluted shares, weighted	129m	128m	33m	+0.2%	+289.0%
Shares outstanding at period end	129m	128m	129m	+0.6%	-0.1%

Cash flow lines for the quarter; where the company files them year to date, the quarter is the difference between two filings.

Balance sheet

$ million	Q3 FY2026	Q2 FY2026	Q3 FY2025	On the quarter	On the year
Shareholders' equity	381	456	-566	-16.4%
Non-controlling interest	0.0	0.0	n/a
Redeemable equity	0.0	0.0	n/a
Debt	0.0	0.0	n/a
Operating lease liabilities	46.1	47.6	n/a	-3.2%
Finance lease liabilities	5.9	1.4	n/a	+331.3%
Other liabilities	82.7	56.6	n/a	+46.1%
Total liabilities and equity	516	562	n/a	-8.2%
Fixed assets	38.7	27.3	n/a	+41.6%
Investments	264	322	n/a	-18.1%
Cash and equivalents	140	135	119	+3.7%	+18.4%
Other assets	73.0	77.0	n/a	-5.1%
Total assets	516	562	n/a	-8.2%

Questions

What was Generate Biomedicines' revenue in Q3 FY2026?

Generate Biomedicines (GENB) reported revenue of $4 million for Q3 FY2026, the quarter ended 30 September 2026, down 56.2% on the same quarter a year earlier.

How much did Generate Biomedicines earn in Q3 FY2026?

Net loss for Q3 FY2026 was $88 million, and the diluted loss per share $0.68.

When did Generate Biomedicines report Q3 FY2026 results?

Generate Biomedicines filed its 10-Q for the quarter ended 30 September 2026 with the SEC on 12 November 2026.

Quarterly results, the last 6 quarters

	Q1 FY2025	Q2 FY2025	Q3 FY2025	Q1 FY2026	Q2 FY2026	Q3 FY2026
Revenue	8.8	10.1	9.6	7.2	6.3	4.2
R&D	46.8	59.7	62.2	57.8	64.3	82.3
Operating income	-48.2	-60.1	-62.8	-64.1	-71.6	-91.5
Operating margin	-546%	-594%	-652%	-887%	-1134%	-2168%
Interest expense	0.4	0.3	0.3	0.2	0.2	0.2
Pre-tax income	-44.3	-56.7	-60.0	-61.7	-67.2	-87.6
Net income	-41.7	-52.4	-53.6	-61.4	-67.3	-87.7
Net margin	-473%	-518%	-557%	-851%	-1065%	-2077%
Diluted EPS	-$0.81	-$1.94	-$1.97	-$0.54	-$0.52	-$0.68
Operating cash flow	-53.2	-48.8	-48.4	-80.4	-57.9	-54.9
Capital expenditure	0.8	0.2	0.2	3.8	0.9	2.2
Free cash flow	-53.9	-48.9	-48.7	-84.2	-58.9	-57.0
Shares outstanding	256m	128m	129m	256m	128m	129m
Filing	10-Q	10-Q	10-Q	10-Q	10-Q	10-Q

Each quarter as filed, linked to its filing.

Money is in $ million as the company files it, or in $ billion by the switch above the tables; per share figures and the share count are as they are. Free cash flow is operating cash flow less capital expenditure; the effective tax rate is income tax over pre-tax income; margins are the line over revenue. Gross profit is revenue less cost of revenue, and operating income is revenue less the company's own total costs, where the statement does not print those lines. Cash flow lines filed year to date are the difference between two filings. Shares outstanding are at the period end where the balance sheet tags them, otherwise the count on the filing's cover page. A derived fourth-quarter EPS is left blank when a split in the year makes the arithmetic meaningless.

10-Q for the period ended 30 September 2026, filed 12 November 2026: the filing.